

EDO-S101
Dexamethasone
Bortezomib
Bortezomib + Dexa
EDO + Dexa
EDO + Bortezomib
EDO + Bortezomib + Dexa
MTT metabolization (% of control)
100
80
60
40
20
0
Control
EDO 500nM
EDO 1µM
EDO 2µM

Figure 1



EDO-S101
Dexamethasone
Bortezomib
Bortezomib + Dexa
EDO + Dexa
EDO + Bortezomib
EDO + Bortezomib + Dexa
MTT metabolization (% of control)
100
80
60
40
20
0
Control
EDO 500nM
EDO 1µM
EDO 2µM

Figure 2



Control
Bortezomib
Dexamethasone
EDO-S101
BorDex
BorEDO
DexEDO
BorDexEDO
2500.00
2000.00
1500.00
1000.00
500.00
0.00
0
5
10
15
20
25

Figure 3



cell viability [% of untreated control]
bendamustin [µM]
bzb [nM]
cfz [nM]
LU-102 [µM]
edo [µM]

Figure 4



2013-10-16 MTS AMO abzb
cell viability [% of untreated control]
0 10 20 30 40 50 60 70 80 90 100 110
bzb [nM]
0 1.25 2.5 5 10 20
edo [µM]
0 2 4 8
2013-10-16 MTS AMO abzb
cell viability [% of untreated control]
0 10 20 30 40 50 60 70 80 90 100 110
cfz [nM]
0 1.25 2.5 5 10 20
edo [µM]
0 2 4 8
2013-10-16 MTS AMO abzb
cell viability [% of untreated control]
0 10 20 30 40 50 60 70 80 90 100 110
LU-102 [µM]
0 1 3.3 10
edo [µM]
0 2 4 8

Figure 5



2014-01-15 MTS Jeko
cell viability [% of untreated control]
edo [µM]
bzb [nM]
cfz [µM]
LU-102 [µM]

Figure 6



2014-01-15 MTS Granta
cell viability [% of untreated control]
0
10
20
30
40
50
60
70
80
90
100
110
edo [µM]
0
2
4
8
bzb [nM]
0
5
10
20
2014-01-15 MTS Granta
cell viability [% of untreated control]
edo [µM]
0
2
4
8
bzb [nM]
0
5
10
20
2014-01-15 MTS Granta
cell viability [% of untreated control]
edo [µM]
0
2
4
8
LU-102 [µM]
0
1
3.3
10

Figure 7



2014-02-21 MTS MDA-MB468
cell viability [% of untreated control]
edo [µM]
bzb [nM]
cfz [nM]
LU-102 [µM]

Figure.8



MTS HL60 mittel (2)
cell viability [% of untreated control]
edo [µM]
bzb [nM]
MTS HL60 mittel (4)
cell viability [% of untreated control]
edo [µM]
cfz [µM]
MTS HL60 mittel (5)
cell viability [% of untreated control]
edo [µM]
LU-102 [µM]

Figure 9



MTS U937 mittel (3)
cell viability [% of untreated control]
edo [µM]
LU-102 [µM]
MTS U937 mittel (2)
cell viability [% of untreated control]
edo [µM]
cfz [µM]
MTS U937 mittel (2)
cell viability [% of untreated control]
edo [µM]
bzb [nM]

Figure 10



MTS BJAB mean (2)
cell viability [% of untreated control]
edo [µM]
bzb [nM]
MTS BJAB mean (2)
cell viability [% of untreated control]
edo [µM]
cfz [nM]
MTS BJAB mean (3)
cell viability [% of untreated control]
edo [µM]
LU-102 [µM]

Figure 11



MTS OciLy3 mean (4)
cell viability [% of untreated control]
edo [µM]
LU-102 [µM]
MTS OciLy3 mean (3)
cell viability [% of untreated control]
edo [µM]
ctz [nM]
MTS OciLy3 mean (3)
cell viability [% of untreated control]
edo [µM]
bzb [nM]

Figure 12



MTS TMD8 mean(4)
cell viability [% of untreated control]
110
100
90
80
70
60
50
40
30
20
10
0
0
0.5
1
2
edo [µM]
0
2.5
5
10
bzb [nM]
MTS TMD8 mean(4)
cell viability [% of untreated control]
edo [µM]
czl [nM]
MTS TMD8 mean(5)
cell viability [% of untreated control]
edo [µM]
LU-102 [µM]
0
1
3.3
10

Figure 13



MTS BT549 mean(2)
cell viability [% of untreated control]
edo [µM]
bzb [nM]
cfz [nM]
LU-102 [µM]

Figure 14



U87MG
T251MG
T98G
Surviving fraction
1
0.1
0.01
0.001
0
2
4
6
Dose (Gy)
Basal
NL-101 (5.0μM)
NL-101 (2.5μM)
EDO-S101 5.0μM
EDO-S101 2.5μM
*
**

Figure 15